This article is more than 5 years old. Information may no longer be current.

Genentech begins phase 2 clinical trial of ranibizumab port delivery system for wet AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Genentech has initiated a phase 2 clinical trial of the ranibizumab port delivery system implant in patients with wet age-related macular degeneration, according to a company announcement.

The Long Acting Delivery of Ranibizumab (LADDER) study will evaluate the safety and efficacy of the ranibizumab port delivery system (RPDS) implant for the sustained delivery of Lucentis for the treatment of wet AMD.

“With the investigation of the RPDS implant, we hope to provide patients with maximum benefits of treatment with Lucentis while reducing the number of office visits and injections they require,” Jill Hopkins, MD, medical director of Genentech Ophthalmology, said in the announcement.

The RPDS implant has received fast track designation from the FDA, the announcement said. It was well tolerated, improved best corrected visual acuity and was comparable to monthly ranibizumab injections in an earlier phase 1 study.